Drug intelligence / Profile preview

IMD-110

Development stage: Unknown
Lead developer: ImmunSYS
Modality: Small Molecules

Overview

IMD-110 is a small molecule checkpoint kinase (CHK) inhibitor being developed by ImmunSYS. It is designed to target the DNA damage response (DDR) pathway by inhibiting checkpoint kinases, which are critical regulators of the cell cycle. By blocking these kinases, the drug prevents cancer cells from repairing DNA damage, leading to genomic instability and apoptosis. IMD-110 is currently in Phase 1 clinical development for the treatment of prostatic cancer. While it was previously identified for bladder cancer, that indication is currently listed as inactive in the company's development pipeline.

Targets

CHEK1 (Checkpoint kinase 1)

Beyond the preview

Go deeper on IMD-110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMD-110.

Explore the full profile